Drug Database
MI

Microspheres

✓ Approved

TTY Biopharm · therapeutic agent

What is Microspheres?

Microspheres is a therapeutic agent developed by TTY Biopharm. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyTTY Biopharm
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, TTY Biopharm

Therapeutic Indications

Microspheres is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-09-18

Cabbage-Inspired Graphene Aerogel Microspheres as Efficient Micro-Reactors for High-Yield Production of Short Carbon Nanotubes Toward Li+ Battery.

Cheng Yu Y, Tang Qi Q, Yu Zhenfu Z, Hu Ran R et al.

Lithium-ion batteries (LiBs) face critical challenges with graphite anodes, including limited theoretical capacity and sluggish Li+ diffusion kinetics leading to safety risks. Short carbon nanotubes (CNTs) offer compelling advantages due to shortened Li+ diffusion pathways and abundant defect-mediated active sites, yet scalable fabrication remains hindered by harsh preparation processes or low yield/purity. Herein, we report an innovative spatially confined CNTs growth strategy that utilizes cabbage-inspired graphene aerogel microspheres as efficient micro-reactors for high-yield production of defect-rich shortened CNTs. The unique aerogel microspheres with hierarchical pore architecture simultaneously maximizes the dispersion/exposure of nano-catalysts of metal, facilitates rapid propylene (C3H6) gas diffusion, and physically confines the CNTs longitudinal growth, enabling an unprecedented growth yield of 385.58 gg- 1 cat in 1 h. The resulting short CNTs demonstrate superior LiBs anode performances compared with commercial graphite, exhibiting a high specific capacity of 468.73 mAhg- 1 and maintaining a great Coulombic efficiency of 98% at 0.2 C even after 100 cycles. This work develops a generalizable confined-growth paradigm for synthesizing advanced nanocarbons towards energy storage and sustainable valorization of hydrocarbons.

PMID 42758913
Read full article →
PubMedJournal of nanobiotechnology2026-09-18

Simultaneous broad-spectrum antibacterial and regenerative therapy for diabetic wounds using sonosensitive peptide composite hydrogel.

Lin Yao Y, Xing Baicheng B, Zhang Xiong X, Lu Guanghua G et al.

Diabetic wound infections remain highly refractory to treatment due to persistent bacterial colonization, oxidative stress, dysregulated inflammation, vascular insufficiency, and impaired extracellular-matrix remodeling. Current therapeutic strategies remain limited by poor tissue penetration, inadequate infection control, and ineffective inflammatory-oxidative microenvironment modulation. Here, we engineered a sonosensitive antimicrobial peptide composite hydrogel, FFRK8@ZnO2@fHAMA, by integrating human host-defense-peptide-derived FFRK8, microenvironment-responsive ZnO2 microspheres, and fish-collagen-modified hyaluronic acid methacrylate (fHAMA) into an injectable bioactive matrix. Upon low-intensity pulsed ultrasound (LIPUS) irradiation, this hydrogel acts as a multifunctional regenerative dressing that couple broad-spectrum bacterial eradication with oxidative-stress attenuation, macrophage repolarization, angiogenic activation and extracellular-matrix reconstruction. Distinct from conventional passive dressings or antibiotic-dependent therapies, FFRK8@ZnO2@fHAMA enables non-invasive and spatiotemporally precise activation, sustained local therapeutic retention and coordinated immune-redox-metabolic microenvironment remodeling while maintaining favorable biosafety. This sonosensitive peptide hydrogel offers a powerful bioactive strategy for repairing infected diabetic wound and may inspire next-generation therapeutic modality for chronic non-healing tissue regeneration.

PMID 42754894
Read full article →
PubMedMaterials today. Bio2026-09-18

Porosity-engineered long-acting protopanaxadiol microspheres prevent CDK4/6 inhibitor-induced myelosuppression.

Zhang Anan A, Zhu Yunjing Y, Kong Xinyu X, Liu Zixu Z et al.

CDK4/6 inhibitor-induced myelosuppression frequently necessitates treatment interruption or dose reduction, yet effective pharmacological interventions specifically addressing this persistent hematological toxicity remain limited. Here, we report a porosity-programmed protopanaxadiol-loaded PLGA microsphere (PPD-MS) system for rapid-onset and long-acting myeloprotection during anticancer treatment. Using a continuous-flow O/W microsphere fabrication strategy, microsphere porosity and core-shell architecture were precisely regulated by tuning aqueous-phase osmotic pressure, establishing a controllable process-structure-release relationship. The optimized PPD-MS rapidly achieved a stable plasma plateau within 0.5 h after intramuscular injection and maintained sustained systemic exposure for 19 days, with a strong in vitro-in vivo correlation between release profiles (R2 = 0.9983). Their narrow particle-size distribution enabled smooth administration through a 26G needle, supporting clinical feasibility. In chemotherapy- and CDK4/6 inhibitor-induced myelosuppression models, PPD-MS effectively restored peripheral blood cell counts, bone marrow cellularity, and hematopoietic stem and multipotent progenitor populations. Mechanistically, PPD-MS rescued hematopoietic cell-cycle progression by activating PI3K/AKT signaling, suppressing p21-mediated inhibition, and restoring the Rb/E2F1-Cyclin E/CDK2 axis, thereby reversing CDK4/6 inhibitor-induced G1/S arrest. Moreover, combination treatment with paclitaxel or CDK4/6 inhibition enhanced antitumor efficacy, accompanied by increased cytotoxic immune activation and reduced PD-L1-associated immune escape. Collectively, this study establishes a porosity-engineered long-acting microsphere platform that integrates predictable drug release, rapid and sustained myeloprotection, and improved combination anticancer therapy, providing a translational strategy for managing CDK4/6 inhibitor-associated hematological toxicity.

PMID 42756618
Read full article →
PubMedEuropean journal of nuclear medicine and molecular imaging2026-09-18

Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study.

Liao Yong Y, Huang Xin X, Liang Ziwei Z, Ma Junpeng J et al.

Extrahepatic collateral supply from the inferior phrenic artery (IPA) is frequently observed in patients with hepatocellular carcinoma (HCC) undergoing yttrium-90 selective internal radiation therapy (90Y-SIRT). Currently, no standardized IPA management algorithm has been established. This study aimed to propose stratified interventional strategies for IPA and compare the safety and oncological outcomes between two mainstream approaches. A retrospective analysis was performed on 290 consecutive unresectable HCC patients treated with 90Y-SIRT between October 2022 and December 2025. Patients with suspected IPA tumor perfusion on pre-treatment cross-sectional imaging were enrolled. All patients underwent superselective IPA catheterization under combined digital subtraction angiography (DSA) and cone-beam computed tomography (CBCT). According to tumor volume and anatomical characteristics of non-target vessels, patients were divided into direct Y-90 infusion group and IPA embolization group. Tumor response and treatment-related adverse events were assessed and compared. A total of 78 patients with angiographically confirmed IPA tumor supply were finally enrolled, including 45 patients in the IPA Y-90 infusion group and 33 in the IPA embolization group. The median administered radioactivity via IPA was 0.3 GBq. Based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), the objective response rates (ORRs) at 1 and 3 months were 60.0% and 82.3% in the infusion group, versus 48.5% and 69.7% in the embolization group. The compensatory distribution rate of Y-90 microspheres in the original IPA-perfused regions reached approximately 88.0% after IPA embolization. Only mild, reversible thoracic adverse events were noted in both groups, with no severe treatment-related complications. DSA-CBCT combined evaluation is essential for pre-procedural IPA anatomical assessment. Direct Y-90 microsphere infusion via IPA yields superior tumor control when non-target vessels are manageable and IPA-perfused tumor volume ≥ 20 mL. IPA embolization is a reliable alternative for patients with untreatable non-target branches or tumor volume < 20 mL. Both strategies demonstrate favorable safety profiles. The proposed stratified algorithm represents a preliminary approach that warrants further external validation for IPA management during 90Y-SIRT for HCC.

PMID 42754697
Read full article →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-09-17

Anisotropy-Engineered Porous Magnetic Microspheres for Low-Frequency Electromagnetic Absorption.

Liu Min M, Qin Jiazhuan J, Liu Mengni M, Yan Zhikai Z et al.

Magnetic microspheres with tunable magnetic characteristics and structural versatility are promising for electromagnetic (EM) functional materials, yet their development remains limited by the trade-off between magnetic performance and material density. Here, we report anisotropy-engineered porous magnetic microspheres constructed through an ion-engineering strategy, enabling simultaneously enhanced magnetic loss and reduced density without compromising magnetic functionality. Inverted-cone pores introduce strong structural anisotropy, driving magnetic moment reconfiguration, complex domain evolution, and directional magnetic interactions. This anisotropic porous framework further promotes interparticle magnetic coupling and establishes a multiscale magnetic response network for efficient EM energy dissipation. Importantly, tuning the pore aperture enables precise regulation of magnetic response, providing additional structural and functional versatility. Unlike conventional hollow or core-shell architectures, this design preserves the magnetic core while integrating anisotropic porosity, enabling concurrent enhancement of magnetic loss, interfacial polarization, and magnetic coupling. Consequently, the optimized ICFM-3 achieves an extended effective absorption bandwidth (EAB) of 2.88 GHz (5.12-8.00 GHz) at a mere 2.8 mm thickness, demonstrating efficient attenuation performance in the C-band. These findings establish anisotropy engineering as a general strategy for lightweight high-performance EM functional materials.

PMID 42750437
Read full article →
PubMedBioactive materials2026-09-17

Porcelain-clay-inspired microsphere hydrogel bioink facilitates bone regeneration via immune-osteogenic regulation.

Lei Shize S, Sun Di D, Zhang Yifan Y, Guo Yaqi Y et al.

High-quality regeneration of large bone defects depends on the coordinated integration of immunomodulation, osteogenic signal presentation, and structural support. However, conventional bioinks often struggle to simultaneously fulfill these key requirements, particularly in terms of the effective utilization of low-dose bone morphogenetic protein 2 (BMP-2) and matching biomechanical interfaces. Inspired by the shaping behavior of traditional porcelain clay, we developed a clay-like microsphere-based hydrogel bioink that integrates biomimetic immunomodulation, low-dose osteogenic factor delivery, and structural support within a single system. In this construct, mesenchymal stem cell membranes (MSCM) functionalized with mildly biotinylated BMP-2 served as the core bioactive interface and were further integrated onto the surface of chitosan microspheres (CSMP). These functionalized microspheres were subsequently assembled with a gelatin methacryloyl (GM) continuous phase to form a microsphere-composite hydrogel, termed BMP2@MSCM/CSMP + GM, which exhibited rheological and shaping characteristics similar to porcelain clay. Both in vitro and in vivo results demonstrated that this system synergistically optimizes the immune and osteogenic microenvironments, thereby promoting bone-related regenerative processes and achieving superior bone repair performance compared with the control groups. This strategy provides an integrated biomanufacturing approach for large bone defect repair by combining bioactive regulation and structural functionality within a single platform.

PMID 42751516
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Microspheres